Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05758363
Other study ID # CE012309
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 9, 2023
Est. completion date November 30, 2023

Study information

Verified date March 2024
Source Universidad Católica San Antonio de Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this randomized, parallel, two-arm, placebo-controlled, double-blind, multicenter clinical trial is to evaluate the efficacy of a dietary supplement on weight loss and psychological well-being in overweight individuals.


Description:

The duration of the study will be 6 months during which the investigational product or placebo will be consumed according to the assignment. Subjects will be randomized to each of the study arms (consumption of the experimental product or control product).


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - Adults (age: 30 - 70 YO) - BMI over 25 kg/m2. - Subjects who are smokers or non-smokers, but in any case who do not modify their nicotinic habits during their participation in the study. Exclusion Criteria: - Subjects with eating disorders. - BMI less than 25 Kg/m2. - History of allergic hypersensitivity or poor tolerance to any component of the products under study. - Participation in another clinical trial in the three months prior to the study. - Unwillingness or inability to comply with clinical trial procedures. - Pregnant woman. - Participants with an active daily exercise activity. - Subjects whose condition makes them ineligible for the study at the investigator's discretion.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Consumption of dietary supplement.
Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
Other:
Consumption of control product
Consumption of 1 capsule per day of control product of identical appearance with breakfast.

Locations

Country Name City State
Spain UCAM San Antonio Catholic University of Murcia Murcia

Sponsors (1)

Lead Sponsor Collaborator
Universidad Católica San Antonio de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of weight loss Evaluation of weight loss by assessment of anthropometric measurements - Waist/hip ratio - Waist/height ratio. From baseline to 6 months later
Secondary Quality of life by WHOQOL-BREF World Health Organization Quality of Life Brief version test. The raw scores are transformed into a normalized scale ranging from 4 to 20 and from 0 to 100. Higher scores indicating better quality of life. From baseline to 6 months later
Secondary Quality of life by SF-36 Short Form 36 Health Survey Questionnaire (SF-36). The SF-36 contains 36 items that measure eight dimensions or scales. The scores for each dimension will be calculated in both raw and transformed form as indicated in the manual, with higher scores indicating better health status for that particular dimension. From baseline to 6 months later
Secondary Depression Beck Depression Inventory test. The score ranges from 0 to 63, where the higher the score, the greater the signs of depression. From baseline to 6 months later
Secondary Stress Perceived Stress Scale (PSS). Total scores range from 0 to 56 (higher scores indicate higher levels of stress). From baseline to 6 months later
Secondary Anxiety State-Trait Anxiety Inventory (STAI) Test. Scores can vary between 0 to a maximum of 60. Higher scores correlate positively with higher levels of anxiety. From baseline to 6 months later
Secondary Dietary intake Registration and subsequent nutritional evaluation with 3-day food frequency questionnaire (FFQ). From baseline to 6 months later
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4